Allergic Conjunctivitis Market to Hit USD 4.26 Billion by 2030; Growing Patient Population and Demand for Effective Therapeutics to Augment Market Growth

The global allergic conjunctivitis market size was USD 2.74 billion in 2022. The market is projected to grow from USD 2.89 billion in 2023 to USD 4.26 billion by 2030, exhibiting a CAGR of 5.7% during the forecast period. Fortune Business Insights™ presents this information in its report titled, “Allergic Conjunctivitis Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Antihistamines & Mast Cell Stabilizers, Corticosteroids, and Others), By Disease Type (Mild Allergic Conjunctivitis, and Severe Allergic Conjunctivitis), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies), and Geographical Forecast, 2023-2030”.

Allergic conjunctivitis is a common ophthalmic disorder where the eye's conjunctiva develops an inflammation due to an allergic reaction resulting from an individual’s interaction with an allergen. This disease is disturbing a considerable proportion globally but may often be ignored and underdiagnosed.

Inadequate Visits to Ophthalmologists during COVID-19 Pandemic Impacted Market Negatively 

The outbreak of COVID-19 resulted in stringent lockdowns to mitigate the effects of the spread of the disease. The strict regulations imposed resulted in a severe decrease in ophthalmologist visits, slowing the adoption of ocular allergy treatments and revenue realization. The market witnessed pre-COVID-19 growth due to the recovery of delayed treatments and new product launches. Hence, the allergic conjunctivitis market growth witnessed a downfall during the projected period.

Rising Patient Population to Foster Demand for Effective Therapeutics

One of the most important contributors to global market growth is the substantial patient population suffering from ocular allergies. Allergy is a serious medical problem predicted to disturb more than 15% of the global population. The ocular component is considered the most important and restricting feature of an allergy.

Ocular Therapeutix in Collaboration with AffaMed Therapeutics to Drive Market Development

Ocular Therapeutix, with AffaMed Therapeutics, declared a license agreement and a collaboration for the development and commercialization of DEXTENZA and OTX-TIC in South Korea, the ASEAN, and Greater China markets. DEXTENZA is presently accepted in the U.S. for the treatment of post-surgical ocular inflammation and pain and is currently in the Phase III stage of clinical trials as a potential treatment for allergic conjunctivitis.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/industry-reports/allergic-conjunctivitis-market-100121

Competitive Landscape:

Strong Product Portfolio of Leading Players to Allow Apex Position

Companies in the market such as Alembic Pharmaceuticals Limited and Sun Pharmaceuticals are growing their presence in the market globally by focusing on product approvals and the launch of generic versions of existing drugs. Moreover, emerging players such as Eton Pharmaceuticals and Ocular Therapeutix, Inc. are also focusing to gain regulatory approvals for their pipeline candidates, and this is anticipated to permit them to grow their revenues during the projected period.

Notable Industry Development:

• February 2021: Alcon declared the broad retail availability of Pataday Once Daily Relief Extra   Strength in the U.S.

Further Report Findings:

• North America dominated the allergic conjunctivitis market share during 2022 and is projected to continue its dominance during the projected period. The dominance in this region is caused due to the widespread awareness of ocular allergies, the occurrence of this disease, and the presence of major players resulting in the launches of advanced drugs.


• Europe is estimated to grow as the second-largest region in the global market due to the growing potential population and the growing usage of sophisticated drugs.


• The other regions, such as Latin America & the Middle East & Africa, is expected to account for a comparatively minor market share during the projected period. However, the increased market presence of prominent companies and a large proportion of the population suffering from ocular allergies in these regions are predicted to lead the growth in the future.

List of Key Market Players Profiled in the Report:

• Allergan (AbbVie Inc.) (U.S.)


• Santen Pharmaceutical Co., Ltd. (Japan)


• Bausch & Lomb Incorporated (Canada)


• Alcon (Switzerland)


• Novartis AG (Switzerland)


• Eyevance Pharmaceuticals LLC (U.S.)


• Sun Pharmaceutical Industries Ltd. India)


• Ocular Therapeutix, Inc. (U.S.)


• Eton Pharmaceutical (U.S.)

Table of Segmentation: